Table 5 Association between the PMT constructs and examined allergy management measures

 Seriousness

2.12 (1.56–2.89)**

1.04 (0.77–1.41)

0.95 (0.65–1.40)

1.13 (0.81–1.56)

0.72 (0.54–0.96)*†

 Severity

1.35 (1.02–1.81)*

1.60 (1.21–2.11)**

1.65 (1.16–2.35)**

0.83 (0.61–1.13)

2.12 (1.60–2.81)**

 Response efficacy

1.16 (0.83–1.62)

1.00 (0.73–1.38)

1.40 (0.96–2.06)

1.08 (0.78–1.58)

1.04 (0.77–1.42)

 Response costs

1.34 (1.03–1.73)

0.88 (0.67–1.13)

1.09 (0.79–1.51)

1.25 (0.95–1.64)

1.28 (1.00–1.64)

 Self-efficacy

4.52 (3.11–6.56)**

1.37 (0.99–1.90)*

1.52 (1.01–2.28)*

0.97 (0.67–1.32)

1.46 (1.07–1.99)*†

 Allergy experience

1.00 (0.98–1.03)

1.02 (1.00–1.04)

1.04 (1.00–1.07)*†

1.00 (0.98–1.03)

1.01 (0.99–1.03)

 Gender (female)

1.17 (0.79–1.63)

1.44 (1.25–2.26)*†

1.25 (0.96–2.17)

0.70 (0.45–1.11)

1.03 (0.81–1.69)

 Medical supervision ^a

0.39 (0.25–0.86)**

2.22 (1.48–3.35)*

9.80 (8.16–13.80)**

0.66 (0.44–1.09)

 Self-management ^a

4.76 (2.67–7.49)**

0.91 (0.59–1.51)

2.56 (1.87–3.52)**

 Anti-allergic medication ^a

1.26 (0.66–2.40)

1.17 (0.67–1.87)

 Specific immunotherapy ^a

1.09 (0.67–1.78)